BRAF and non-small cell lung carcinoma: The results of another real-world study showed that among 40 patients with advanced NSCLC harboring the BRAF V600E mutation, the median PFS and median OS for the treatment with dabrafenib combined with trametinib were 17.5 months (95% CI: 7.1–23 months) and 25.5 months (95% CI: 16.6 months—not reached), respectively.